ABUS vs CCL · P/E 5.4, rev $6.2M vs P/E 15, rev $25.02B
Arbutus Biopharma Corp (ABUS) versus Carnival Corporation (CCL) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Carnival Corporation (CCL) is a travel services company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported CCL revenue for 2024-11-30 was $25.02B. Net income was $1.92B. Revenue was up 15.9% from 2023-11-30 to 2024-11-30. CCL currently screens at market cap $39.74B and trailing P/E 15.3.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. CCL currently screens at market cap $39.74B and trailing P/E 15.3.
Not investment advice. Open the ABUS and CCL stock pages for the full models.
Not investment advice.